pravastatin has been researched along with Pulmonary Hypertension in 6 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 6 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Demachi, J; Fukumoto, Y; Ishii, N; Kagaya, Y; Karibe, A; Nakano, M; Nawata, J; Satoh, K; Shimokawa, H; Sugamura, K; Sugimura, K | 1 |
| Chang, NC; Chen, CC; Lee, TM; Shen, HN | 1 |
| Corte, TJ; Wort, SJ | 1 |
| Satoh, A; Satoh, M | 1 |
| Bardou, M; Dumas, M; Goirand, F; Guerard, P; Lirussi, F; Rakotoniaina, Z; Rochette, L | 2 |
1 trial(s) available for pravastatin and Pulmonary Hypertension
| Article | Year |
|---|---|
Effects of pravastatin on functional capacity in patients with chronic obstructive pulmonary disease and pulmonary hypertension.
Topics: Adult; Aged; Aged, 80 and over; Endothelin-1; Exercise Tolerance; Female; Hemodynamics; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypertension, Pulmonary; Lipids; Male; Middle Aged; Pravastatin; Pulmonary Disease, Chronic Obstructive; Treatment Outcome | 2009 |
5 other study(ies) available for pravastatin and Pulmonary Hypertension
| Article | Year |
|---|---|
Statin ameliorates hypoxia-induced pulmonary hypertension associated with down-regulated stromal cell-derived factor-1.
Topics: Actins; Animals; Bone Marrow Cells; CD18 Antigens; Cell Differentiation; Cells, Cultured; Chemokine CXCL12; Disease Models, Animal; Down-Regulation; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypertension, Pulmonary; Hypoxia; Intercellular Adhesion Molecule-1; Mice; Mice, Inbred BALB C; Muscle, Smooth, Vascular; Pravastatin; Proto-Oncogene Proteins c-kit; Receptors, CXCR4; Stem Cells; Vascular Endothelial Growth Factor Receptor-2 | 2009 |
Role of pravastatin in pulmonary hypertension in chronic obstructive pulmonary disease.
Topics: Exercise Tolerance; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypertension, Pulmonary; Pravastatin; Pulmonary Disease, Chronic Obstructive | 2009 |
3-Hydroxy-3-methylglutaryl (HMG)-COA reductase inhibitors and phosphodiesterase type V inhibitors attenuate right ventricular pressure and remodeling in a rat model of pulmonary hypertension.
Topics: Animals; Atorvastatin; Disease Models, Animal; Hemodynamics; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypertension, Pulmonary; Male; Monocrotaline; Phosphodiesterase Inhibitors; Pravastatin; Pulmonary Artery; Pyrroles; Rats; Rats, Wistar; Simvastatin | 2009 |
The HMG-CoA reductase inhibitor, pravastatin, prevents the development of monocrotaline-induced pulmonary hypertension in the rat through reduction of endothelial cell apoptosis and overexpression of eNOS.
Topics: Acetylcholine; Animals; Apoptosis; Blood Pressure; Blotting, Western; Body Weight; Caspase 3; Disease Progression; Endothelial Cells; Heart Function Tests; Heart Rate; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypertension, Pulmonary; Hypertrophy, Right Ventricular; Immunohistochemistry; In Situ Nick-End Labeling; Lung; Male; Monocrotaline; Nitric Oxide Synthase Type III; Nitroprusside; Poisons; Pravastatin; Pulmonary Artery; Rats; Rats, Wistar; Survival; Vasodilator Agents | 2006 |
The protective effect of HMG-CoA reductase inhibitors against monocrotaline-induced pulmonary hypertension in the rat might not be a class effect: comparison of pravastatin and atorvastatin.
Topics: Acetylcholine; Animals; Apoptosis; Atorvastatin; Caspase 3; Endothelial Cells; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypertension, Pulmonary; Lung; Male; Monocrotaline; Nitric Oxide Synthase Type III; Nitroprusside; Pravastatin; Pulmonary Artery; Pyrroles; Rats; Rats, Wistar; Ventricular Pressure | 2006 |